Literature DB >> 3116071

The effect of terbutaline sulfate, nitroglycerin, and aminophylline on lower esophageal sphincter pressure and radionuclide esophageal emptying in patients with achalasia.

R K Wong1, C Maydonovitch, J E Garcia, L F Johnson, D O Castell.   

Abstract

We studied the effects of three smooth muscle relaxants on lower esophageal sphincter (LES) pressure and radionuclide esophageal emptying in 15 untreated patients with achalasia. LES pressures were determined before and after the administration of normal saline subcutaneously, terbutaline sulfate subcutaneously, nitroglycerin sublingually, and aminophylline intravenously. All smooth muscle relaxants significantly decreased LES pressures when compared with normal saline controls and pretreatment baseline pressures (p less than 0.01). However, in normal saline controls, LES pressure actually increased over time (p less than 0.01). Control radionuclide esophageal emptying studies were performed in all patients. Subsequent esophageal emptying studies were carried out only in patients responding to smooth muscle relaxants by decreasing LES pressures by greater than or equal to 25% (terbutaline sulfate, n = 8; nitroglycerin, n = 7; and aminophylline, n = 4). Significant improvement in esophageal emptying was observed after nitroglycerin and terbutaline sulfate (p less than 0.05) but not after aminophylline. We conclude that in patients with achalasia (a) terbutaline sulfate, nitroglycerin, and aminophylline can significantly decrease LES pressure; (b) resting LES pressures vary over time; and (c) terbutaline sulfate and nitroglycerin significantly improve esophageal emptying in some subjects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116071     DOI: 10.1097/00004836-198708000-00006

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  11 in total

Review 1.  Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.

Authors:  Ammar Nassri; Zeeshan Ramzan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

2.  Treatment of esophageal motility disorders based on the chicago classification.

Authors:  Carla Maradey-Romero; Scott Gabbard; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

Review 3.  Updated Systematic Review of Achalasia, with a Focus on POEM Therapy.

Authors:  Mitchell S Cappell; Stavros Nicholas Stavropoulos; David Friedel
Journal:  Dig Dis Sci       Date:  2019-08-27       Impact factor: 3.199

4.  Body mass index and chronic unexplained gastrointestinal symptoms: an adult endoscopic population based study.

Authors:  P Aro; J Ronkainen; N J Talley; T Storskrubb; E Bolling-Sternevald; L Agréus
Journal:  Gut       Date:  2005-05-25       Impact factor: 23.059

5.  Human lower oesophageal sphincter relaxation is associated with raised cyclic nucleotide content.

Authors:  M S Barnette; F C Barone; P J Fowler; M Grous; W J Price; H S Ormsbee
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

Review 6.  Nitrates for achalasia.

Authors:  Z H Wen; E Gardener; Y P Wang
Journal:  Cochrane Database Syst Rev       Date:  2004

7.  Nitric oxide, an enteric nonadrenergic-noncholinergic relaxant transmitter: evidence using phosphodiesterase V and nitric oxide synthase inhibition.

Authors:  S J Williams; M E Parsons
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

Review 8.  [Treatment of achalasia].

Authors:  Enrico P Cosentini; Etienne Wenzl; Raimund Jakesz
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

Review 9.  A controversy that has been tough to swallow: is the treatment of achalasia now digested?

Authors:  Garrett R Roll; Charlotte Rabl; Ruxandra Ciovica; Sofia Peeva; Guilherme M Campos
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

10.  Descriptive Rules for Achalasia of the Esophagus, June 2012: 4th Edition.

Authors: 
Journal:  Esophagus       Date:  2017-09-05       Impact factor: 4.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.